Patents by Inventor Matthias DREYER
Matthias DREYER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250115669Abstract: Provided herein are FGFR1/KLB targeting agonistic antigen-binding proteins, or fragments thereof, having improved physico-chemical properties. Also provided herein are conjugates comprising an FGFR1/KLB targeting agonistic antigen-binding protein, or a fragment thereof, and at least one GLP-1R agonistic peptide. Further provided are pharmaceutical compositions comprising the antibody (or fragment thereof), or the conjugate provided herein, and the use of the antibody (or fragment thereof), or the use of the conjugate in medicine.Type: ApplicationFiled: June 24, 2024Publication date: April 10, 2025Inventors: Mark SOMMERFELD, Thomas LANGER, Uwe SCHWAHN, Werner DITTRICH, Christine RUDOLPH, Matthias DREYER, Soraya HÖLPER, Christian LANGE, Katrin LORENZ
-
Patent number: 12054551Abstract: Provided herein are FGFR1/KLB targeting agonistic antigen-binding proteins, or fragments thereof, having improved physico-chemical properties. Also provided herein are conjugates comprising an FGFR1/KLB targeting agonistic antigen-binding protein, or a fragment thereof, and at least one GLP-1R agonistic peptide. Further provided are pharmaceutical compositions comprising the antibody (or fragment thereof), or the conjugate provided herein, and the use of the antibody (or fragment thereof), or the use of the conjugate in medicine.Type: GrantFiled: July 1, 2021Date of Patent: August 6, 2024Assignee: SANOFIInventors: Mark Sommerfeld, Thomas Langer, Uwe Schwahn, Werner Dittrich, Christine Rudolph, Matthias Dreyer, Soraya Hölper, Christian Lange, Katrin Lorenz
-
Publication number: 20220227825Abstract: The present invention relates to polypeptide variants of human fibroblast growth factor 21 (FGF21) and fusion molecules thereof, as well as to nucleic acid molecules encoding the same. It further relates to their use as medicaments, in particular for the treatment of obesity, overweight, metabolic syndrome, diabetes mellitus, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and/or atherosclerosis.Type: ApplicationFiled: December 3, 2021Publication date: July 21, 2022Inventors: Mark SOMMERFELD, Thomas LANGER, Oliver BOSCHEINEN, Matthias DREYER, Werner DITTRICH, Paul HABERMANN
-
Patent number: 11230582Abstract: The present invention relates to polypeptide variants of human fibroblast growth factor 21 (FGF21) and fusion molecules thereof, as well as to nucleic acid molecules encoding the same. It further relates to their use as medicaments, in particular for the treatment of obesity, overweight, metabolic syndrome, diabetes mellitus, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and/or atherosclerosis.Type: GrantFiled: December 2, 2016Date of Patent: January 25, 2022Assignee: SANOFIInventors: Mark Sommerfeld, Thomas Langer, Oliver Boscheinen, Matthias Dreyer, Werner Dittrich, Paul Habermann
-
Publication number: 20220010021Abstract: Provided herein are FGFR1/KLB targeting agonistic antigen-binding proteins, or fragments thereof, having improved physico-chemical properties. Also provided herein are conjugates comprising an FGFR1/KLB targeting agonistic antigen-binding protein, or a fragment thereof, and at least one GLP-1R agonistic peptide. Further provided are pharmaceutical compositions comprising the antibody (or fragment thereof), or the conjugate provided herein, and the use of the antibody (or fragment thereof, or the use of the conjugate in medicine.Type: ApplicationFiled: July 1, 2021Publication date: January 13, 2022Inventors: Mark SOMMERFELD, Thomas LANGER, Uwe SCHWAHN, Werner DITTRICH, Christine RUDOLPH, Matthias DREYER, Soraya HÖLPER, Christian LANGE, Katrin LORENZ
-
Publication number: 20210170033Abstract: The invention describes novel conjugates of formula (I) of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein allowing a reversible release of the pharmaceutical agent depending on the glucose concentration.Type: ApplicationFiled: November 30, 2018Publication date: June 10, 2021Inventors: Stefan PETRY, Elisabeth DEFOSSA, Michael PODESCHWA, Volker DERDAU, Hans MATTER, Nis HALLAND, Kaihui HU HE, Matthias DREYER, Maximilian BIELOHUBY, Melissa BESENIUS, Meltsje DE HOOP
-
Publication number: 20190085043Abstract: The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to pharmaceutical compositions, medical uses and methods of treatment involving the fusion protein, particularly in the field of diabetes, dyslipidemia, obesity and/or adipositas.Type: ApplicationFiled: July 27, 2018Publication date: March 21, 2019Inventors: Oliver Boscheinen, Matthias Dreyer, Paul Habermann, Hans-Ludwig Schaefer, Mark Sommerfeld, Thomas Langer
-
Publication number: 20180371041Abstract: The present invention relates to polypeptide variants of human fibroblast growth factor 21 (FGF21) and fusion molecules thereof, as well as to nucleic acid molecules encoding the same. It further relates to their use as medicaments, in particular for the treatment of obesity, overweight, metabolic syndrome, diabetes mellitus, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and/or atherosclerosis.Type: ApplicationFiled: December 2, 2016Publication date: December 27, 2018Inventors: Mark SOMMERFELD, Thomas LANGER, Oliver BOSCHEINEN, Matthias DREYER, Werner DITTRICH, Paul HABERMANN
-
Publication number: 20180236033Abstract: The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.Type: ApplicationFiled: January 11, 2018Publication date: August 23, 2018Inventors: Mark Sommerfeld, Hans-Ludwig Schaefer, Oliver Boscheinen, Paul Habermann, Ercole Rao, Matthias Dreyer
-
Publication number: 20160279199Abstract: The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.Type: ApplicationFiled: March 2, 2016Publication date: September 29, 2016Inventors: Mark Sommerfeld, Hans-Ludwig Schaefer, Oliver Boscheinen, Paul Habermann, Ercole Rao, Matthias Dreyer
-
Publication number: 20160194371Abstract: The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to pharmaceutical compositions, medical uses and methods of treatment involving the fusion protein, particularly in the field of diabetes, dyslipidemia, obesity and/or adipositas.Type: ApplicationFiled: December 10, 2015Publication date: July 7, 2016Inventors: Oliver Boscheinen, Matthias Dreyer, Paul Habermann, Hans-Ludwig Schaefer, Mark Sommerfeld, Thomas Langer
-
Publication number: 20150231210Abstract: The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.Type: ApplicationFiled: February 20, 2015Publication date: August 20, 2015Applicant: SanofiInventors: Mark SOMMERFELD, Hans-Ludwig Schaefer, Oliver Boscheinen, Paul Habermann, Ercole Rao, Matthias Dreyer
-
Publication number: 20140142023Abstract: The invention is directed to a pharmaceutical composition comprising at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas. The invention is also directed to a pharmaceutical composition comprising at least one FGF-21 (fibroblast growth factor 21) compound, at least one DPP-4 (dipeptidyl peptidase-4) inhibitor and optionally GLP-1R (glucagon-like peptide-1 receptor) agonist and/or at least one at least one anti-diabetic drug for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.Type: ApplicationFiled: June 29, 2012Publication date: May 22, 2014Applicant: SANOFIInventors: Mark Sommerfeld, Hans-Ludwig Schaefer, Oliver Boscheinen, Paul Habermann, Ercole Rao, Matthias Dreyer
-
Patent number: 8722671Abstract: The invention relates to 6-piperidinyl-substituted isoquinoline derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.Type: GrantFiled: June 15, 2011Date of Patent: May 13, 2014Assignee: SanofiInventors: Oliver Plettenburg, Armin Hofmeister, Dieter Kadereit, Stefan Peukert, Sven Ruf, Kurt Ritter, Matthias Loehn, Yuri Ivashchenko, Peter Monecke, Matthias Dreyer, Aimo Kannt
-
Publication number: 20140073563Abstract: The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to pharmaceutical compositions, medical uses and methods of treatment involving the fusion protein, particularly in the field of diabetes, dyslipidemia, obesity and/or adipositas.Type: ApplicationFiled: September 6, 2013Publication date: March 13, 2014Applicant: SANOFIInventors: Oliver BOSCHEINEN, Matthias DREYER, Paul HABERMANN, Hans-Ludwig SCHAEFER, Mark SOMMERFELD, Thomas LANGER
-
Publication number: 20130203651Abstract: The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.Type: ApplicationFiled: January 21, 2011Publication date: August 8, 2013Applicant: SANOFIInventors: Mark Sommerfeld, Hans-Ludwig Schaefer, Oliver Boscheinen, Paul Habermann, Ercole Rao, Matthias Dreyer
-
Patent number: 8501736Abstract: The invention relates to 6-piperidinyl-substituted isoquinoline derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.Type: GrantFiled: December 20, 2007Date of Patent: August 6, 2013Assignee: SanofiInventors: Oliver Plettenburg, Armin Hofmeister, Dieter Kadereit, Stefan Peukert, Sven Ruf, Kurt Ritter, Matthias Loehn, Yuri Ivashchenko, Peter Monecke, Matthias Dreyer, Aimo Kannt
-
Publication number: 20110251226Abstract: The invention relates to 6-cyclohexylamine-substituted isoquinolone derivatives of the formula (I) or isoquinoline derivatives of the formula (I?) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.Type: ApplicationFiled: June 15, 2011Publication date: October 13, 2011Applicant: SANOFI-AVENTISInventors: Oliver Plettenburg, Armin Hofmeister, Dieter Kadereit, Stefan Peukert, Sven Ruf, Kurt Ritter, Matthias Loehn, Yuri Ivashchenko, Peter Monecke, Matthias Dreyer, Aimo Kannt
-
Publication number: 20110245248Abstract: The invention relates to 6-piperidinyl-substituted isoquinoline derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.Type: ApplicationFiled: June 15, 2011Publication date: October 6, 2011Applicant: SANOFI-AVENTISInventors: Oliver Plettenburg, Armin Hofmeister, Dieter Kadereit, Stefan Peukert, Sven Ruf, Kurt Ritter, Matthias Loehn, Yuri Ivashchenko, Peter Monecke, Matthias Dreyer, Aimo Kannt
-
Publication number: 20090088429Abstract: The invention relates to 6-piperidinyl-substituted isoquinoline derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.Type: ApplicationFiled: December 20, 2007Publication date: April 2, 2009Applicant: SANOFI-AVENTISInventors: Oliver PLETTENBURG, Armin HOFMEISTER, Dieter KADEREIT, Stefan PEUKERT, Sven RUF, Kurt RITTER, Matthias LOEHN, Yuri IVASHCHENKO, Peter MONECKE, Matthias DREYER, Aimo KANNT